Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

500-Patient study aims to unlock secrets of progressive lung scarring

NCT ID NCT06855329

Knowledge-focused Sponsor: University of Massachusetts, Worcester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This study follows 500 adults with progressive pulmonary fibrosis (a type of lung scarring) for 24 months. Researchers will collect medical images, lung function tests, and blood samples to better classify the disease and predict its course. The goal is to improve how doctors identify and manage this condition, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to identify and predict progressive pulmonary fibrosis, helping doctors tailor treatments earlier.
What could go wrong
This is an observational study, not testing a treatment, so it won't directly change patient care. Results may take years to influence practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with non-idiopathic pulmonary fibrosis (non-IPF) fibrosing ILD, including connective tissue disease associated ILD (CTD-ILD), fibrotic hypersensitivity pneumonitis (fHP) and non-IPF idiopathic interstitial pneumonia (IIP).

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-80 years with a diagnosis of non-IPF fibrosing ILD due to CTD-ILD, fHP, or non-IPF IIP based on central review * Diagnosis of Fibrotic ILD as determined by site investigator. * Willingness to comply with study procedures and follow-up. * Provide written informed consent. Exclusion Criteria: * Site diagnosis of fibrosing ILD \>5 years prior to Visit 1 (Screening and Baseline Visit). * Minimal ILD, defined as reticular opacities and/or ground-glass opacities without architectural distortion (traction bronchiolectasis/bronchiectasis or honeycombing) affecting \< 5% of the lung on centralized evaluation of HRCT at Visit 1 (Screening and Baseline Visit). High quality historical chest HRCT may be used if performed within 90 days prior to Visit 1. * Extent of emphysema \>15% of total lung volume or greater than extent of fibrosis based on central, qualitative assessment of HRCT at Visit 1. High quality historical chest HRCT may be used if performed within 90 days prior to Visit 1. * Active malignancy within one year prior to Visit 1 (except for non-melanoma skin cancer requiring local treatment). * Inability to complete full PFT (spirometry and DLCO) at Visit 1. Historical PFT may be used if performed within 90 days prior to Visit 1. * Taking nintedanib or nerandomilast at Visit 1. * Pregnancy at screening or plans to become pregnant during follow-up. * Participation in an interventional clinical trial for fibrotic ILD at the time of Visit 1, or receipt of an investigational drug within the previous 4 weeks of the enrollment visit (Visit 1) or 5 times the half-life, if longer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibrotic hypersensitivity pneumonitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fibrotic hypersensitivity pneumonitis idiopathic interstitial pneumonia interstitial lung disease pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interstitial lung disease Progressive pulmonary fibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites in 13 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aarhus University Hospital

    NOT_YET_RECRUITING

    Aarhus, 8200, Denmark

  • Austin Health

    NOT_YET_RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Bichat, APHP

    NOT_YET_RECRUITING

    Paris, 75018, France

  • Charles University and Faculty Thomayer Hospital

    NOT_YET_RECRUITING

    Prague, 140 59, Czechia

  • Chu Pontchaillou

    NOT_YET_RECRUITING

    Rennes, 35000, France

  • Erasmus MC

    RECRUITING

    Rotterdam, South Holland, 3015GD, Netherlands

  • Hospital Universitario de La Princesa

    NOT_YET_RECRUITING

    Madrid, 28006, Spain

  • LMU Munich

    NOT_YET_RECRUITING

    Munich, 81377, Germany

  • Medical University of Graz

    NOT_YET_RECRUITING

    Graz, 8036, Austria

  • Prince Charles Hospital

    NOT_YET_RECRUITING

    Brisbane, Queensland, 4032, Australia

  • Prüfzentrum der GWT am Lungenzentrum Coswig

    NOT_YET_RECRUITING

    Coswig, Saxony, 01445, Germany

  • Rimini and Riccione Hospitals, AUSL Romagna

    NOT_YET_RECRUITING

    Rimini, 47923, Italy

  • Royal Prince Alfred Hospital

    NOT_YET_RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Semmelweis University

    NOT_YET_RECRUITING

    Budapest, 1083, Hungary

  • University College Dublin

    RECRUITING

    Dublin, Ireland, D04 T6F4, Ireland

  • University Medical Center Mainz

    RECRUITING

    Mainz, 55131, Germany

  • University of British Columbia

    RECRUITING

    Vancouver, British Columbia, V6Z 1Y6, Canada

  • University of Colorado | Anschutz Medical Campus

    NOT_YET_RECRUITING

    Aurora, Colorado, 80045, United States

  • University of Massachusetts Chan Medical School

    RECRUITING

    Worcester, Massachusetts, 01655, United States

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • University of Texas Southwestern

    RECRUITING

    Dallas, Texas, 75390, United States

  • University of Virginia

    RECRUITING

    Charlottesville, Virginia, 22908, United States

  • University of Washington

    RECRUITING

    Seattle, Washington, 98195, United States

  • Weill Cornell Medicine

    NOT_YET_RECRUITING

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.